Terumo Cardiovascular Group

e-mail usprint

Information provided on this website is not intended to make claims that the products are safe and effective for any use other than those explicitly described in the Instructions for Use. Clinicians should refer to the Instructions for Use or Owner's Manuals for complete information on the intended use of any product mentioned in this website.

ABSTRACT: Intraoperative Treatment Strategy to Reduce the Incidence of Post-Cardiopulmonary Bypass Atrial Fibrillation. Perfusion 2002; V 17. O-Yurvati A.
In this study, the authors demonstrate a 72% reduction in the incidence of post-op atrial fibrillation in patients who receive leukocyte filtration and aprotinin, resulting in $8,725 savings per patient.

ABSTRACT: Non-Pharmacologic Therapeutic Strategies for Reducing Complications of Cardiopulmonary Bypass. Filtration 2005; 1(2):95-106. Gunaydin S, et al.
This study of 225 patients undergoing CPB concludes that the use of circuits with leukocyte filtration and Xcoating provides clinically significant benefits for high risk patients.

ABSTRACT: Clinical Evaluation of a Leuko-Depleting Blood Cardioplegia Filter (BC1B) for Elective Open-Heart Surgery. Perfusion 1998; 13: 205-210. Suzuki, et al.
In this study of 40 CABG patients, the authors demonstrate the ability of the Pall BC1 filter to remove inflammatory mediators CPK-MB and troponin.

ABSTRACT: A Review of Leukofiltration in Cardiac Surgery: The Time Course of Reperfusion Injury may Facilitate Study Design of Anti-Inflammatory Effects. Perfusion 2002; 17: 53-62. Ortolano, et al.
The authors address the effects of systemic inflammatory response syndrome (SIRS) during CPB, and provide a review of leukocyte filtration literature.

ABSTRACT: Leukocyte Filtration and Aprotinin: Synergistic Anti-Inflammatory Protection. Perfusion 2004; Volume 19. O-Yurvati A.
In this follow-up study, Albert O-Yurvati, DO, compares the effects of leukocyte filtration combined with aprotinin versus aprotinin alone to reduce post-operative atrial fibrillation in patients undergoing CPB.

ABSTRACT: Strategic Leukocyte Depletion Reduces Pulmonary Microvascular Pressure and Improves Pulmonary Status Post-Cardiopulmonary Bypass. Perfusion 2003; Volume 18. O-Yurvati A.
Albert O-Yurvati, DO, demonstrates the combination of leukocyte filtration and aprotinin in reducing pulmonary microvascular pressure and shunt fraction in a study of 225 CABG patients.

ABSTRACT: Cost Effectiveness of Using a Leuko-Depleting Arterial Line Filter. Proceedings of the American Academy of Cardiovascular Perfusion 1994: v 15. Palanzo D, et al.
In this study of 350 patients, the authors conclude that the use of the Pall LG6 filter improves post-bypass lung function, and results in $1,942 savings per patient.

ABSTRACT: Clinical Benefits of Continuous Leukocyte Filtration during Cardiopulmonary Bypass in Patients undergoing Valvular Repair or Replacement. Perfusion 2005; V 20: 21-9. Sutton S, et al.
In this retrospective study of 700 patients undergoing valve surgery, the authors demonstrate significant benefits to patients who receive leukocyte filtration, including reduced time to extubation and reduced LOS.

ABSTRACT: The Role of Leukocyte Depleting Filters in Heart Transplantation: Early Outcomes in Prospective, Randomized Clinical Trial. European Journal of Cardiothoracic Surgery. October 2006; 30: 621-627. Dvorak, et al.
In this study of 40 patients, the authors find leukocyte filtration reduces markers of reperfusion injury, time on ventilation and time in the ICU, and improves graft functionality.

ABSTRACT: The Effect of Leukocyte-Depleting Arterial Line Filters on Cerebral Microemboli and Neuropsychological Outcome following Coronary Artery Bypass Surgery. Eur J Cardiothorac Surg 2004; Feb;25(2):267-74. Whittaker, et al
The authors evaluate the effect of using the Pall LG6 arterial line filter on cerebral microemboli and neuropsychological outcome following bypass surgery.